Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional

Satraplatin in Hormone Refractory Prostate Cancer Patients Previously Treated With One Cytotoxic Chemotherapy Regimen

ClinicalTrials.gov ID: NCT00069745

Public ClinicalTrials.gov record NCT00069745. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 1:09 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multi-National Phase III Study of Satraplatin Plus Prednisone or Placebo Plus Prednisone in Patients With Hormone Refractory Prostate Cancer Previously Treated With One Cytotoxic Chemotherapy Regimen

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

PURPOSE: The SPARC trial is designed to compare the combination of the investigational oral cytotoxic drug, satraplatin, and prednisone, versus prednisone alone as second line chemotherapy in patients with hormone-refractory prostate cancer (HRPC). TARGET PATIENT POPULATION: The SPARC trial is intended for patients who have hormone-refractory prostate cancer (HRPC) and whose disease has progressed after treatment with one chemotherapy regimen. Please refer to the Eligibility Criteria page for the key inclusion and exclusion criteria. WHAT IS SATRAPLATIN: Satraplatin is a member of the platinum-based class of chemotherapy drugs. Platinum-based drugs have been clinically proven to be one of the most effective classes of anticancer therapies. Unlike the currently marketed platinum-based drugs, satraplatin can be given orally. Satraplatin is also the only platinum-based drug that has demonstrated efficacy against prostate cancer in a randomized trial. RATIONALE: There are currently no approved chemotherapy drugs for the second line treatment of hormone-refractory prostate cancer (HRPC). In a preliminary randomized trial conducted in Europe, the combination of satraplatin and prednisone had superior activity compared to prednisone alone, for the treatment of HRPC patients who had not previously been treated with chemotherapy

Study identification

NCT ID
NCT00069745
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Agennix
Industry
Enrollment
Not listed

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years and older
Sex
Male
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Sep 2003 (Type not available)
Primary completion
Jan 2006 (Actual)
Completion
Mar 2007 (Actual)
Last update posted
Aug 7, 2012

2003 – 2007

United States locations

U.S. sites
105
U.S. states
32
U.S. cities
93
Facility City State ZIP Site status
Birmingham Hematology and Oncology Birmingham Alabama 35205 —
Birmingham Hematology and Oncology Birmingham Alabama 35235 —
Hematology Oncology Associates Phoenix Arizona 85012 —
Northern AZ Hematology & Oncology Assoc. Sedona Arizona 86336 —
Hematology Oncology Physicians/SMO Tucson Arizona 85712 —
Arizona Cancer Center Tuscon Arizona 85724 —
California Cancer Center Fresno California 93720 —
Pacific Shores Medical Group Long Beach California 90813 —
Division of Hematology - Oncology Los Angeles California 90095-7187 —
University of California Davis Cancer Center, Division of Hematology-Oncology Sacramento California 95817 —
Sharp Healthcare - Clinical Oncology Research San Diego California 92123 —
Rocky Mountain Cancer Center - Midtown Denver Colorado 80218 —
Hartford Hospital Hartford Connecticut 06102 —
DeQuattro Community Cancer Center Manchester Connecticut 06040 —
Cancer Centers of Florida-Altamonte Altamonte Springs Florida 34761 —
The Center for Hematology Oncology Boca Raton Florida 33486 —
Hematology/Oncology Group of South Florida Miami Florida 33176 —
Innovative Medical Research of South Florida Miami Shores Florida 33179 —
Florida Cancer Institute New Port Richey Florida 34655 —
Ocala Oncology Center Ocala Florida 34474 —
South Florida Oncology & Hematology Plantation Florida 33324 —
Hematology/Oncology Associates of Treasure Coast Port Saint Lucie Florida 34952 —
Oncology and Hematology Associates of West Broward P.A. Tamarac Florida 33321 —
Decatur Memorial Hospital Decatur Illinois 62526 —
Northwest Medical Specialists Niles Illinois 60714 —
North Shore Research Association Skokie Illinois 60076 —
Central Indiana Cancer Centers Fishers Indiana 46227 —
Indiana Hematology Oncology Consultants Indianapolis Indiana 46202 —
Central Indiana Cancer Centers Indianapolis Indiana 46227 —
Oncology Associates of Cedar Rapids Cedar Rapids Iowa 52403 —
Kansas City Cancer Centers - Southwest Overland Park Kansas 66210 —
Louisiana Oncology Associates Lafayette Louisiana 70506 —
LSU Health Science Center, Stanley S. Scott Cancer Center New Orleans Louisiana 70112 —
Maine Center for Cancer Medicine & Blood Disorders Scarborough Maine 04074 —
Berkshire Hematology Oncology Pittsfield Massachusetts 01201 —
Karmanos Cancer Institute, Wayne State University Detroit Michigan 48201 —
Maplewood Cancer Center Maplewood Minnesota 55404 —
Virginia Piper Cancer Institute Minneapolis Minnesota 55407 —
Missouri Cancer Associates Columbia Missouri 65201 —
Capitol Comprehensive Cancer Care Clinic Jefferson City Missouri 65109 —
St. Joseph Oncology, Inc. Saint Joseph Missouri 64507 —
Hematology/Oncology Consultants, Inc. St Louis Missouri 63136 —
Arch Medical Services, Inc. Washington Missouri 63090 —
Nebraska Methodist Hospital Cancer Center Omaha Nebraska 68114 —
Comprehensive Cancer Centers of Nevada Las Vegas Nevada 89109 —
Nevada Cancer Institute Las Vegas Nevada 89135 —
New Hampshire Oncology-Hematology PA Hooksett New Hampshire 03106 —
Hematology Oncology Associates Albuquerque New Mexico 87106 —
Lovelace Sandia Health Systems Albuquerque New Mexico 87108 —
Veterans Affairs Medical Center Albuquerque New Mexico 87108 —
The University of New Mexico Albuquerque New Mexico 87131-0001 —
New Mexico Cancer Care Associates Santa Fe New Mexico 87505 —
Albany Regional Cancer Center Albany New York 12208 —
New York Oncology Hematology, P.C. Albany New York 12208 —
Advanced Oncology Associates Armonk New York 10504 —
Roswell Park Cancer Institute Buffalo New York 14263 —
Interlakes Oncology Hematology Canandaigua New York 14623 —
Columbia Presbyterian Medical Center New York New York 10032 —
New York Oncology Hematology Rexford New York 12148 —
VA Medical Center Syracuse Syracuse New York 13210 —
Raleigh Hematology Oncology Clinic Cary North Carolina 27511 —
Piedmont Hematology - Oncology Winston-Salem North Carolina 27103 —
Dayton Oncology Hematology Kettering Ohio 45067 —
Cancer Care Associates Oklahoma City Oklahoma 73120 —
Cancer Care Associates Tulsa Oklahoma 74136 —
Willamette Valley Cancer Center Eugene Oregon 97401 —
Hematology and Oncology Associates of Northeastern PA / PC Dunmore Pennsylvania 18512 —
University of Pennsylvania Abramson Cancer Center Philadelphia Pennsylvania 19104 —
University of Pittsburgh Cancer Institute- Hillman Cancer Center Pittsburgh Pennsylvania 15232 —
Charleston Cancer Center Charleston South Carolina 29406 —
Medical University of South Carolina Hollings Cancer Center Charleston South Carolina 29425 —
Cancer Center of the Carolinas, Seneca Seneca South Carolina 29672 —
The West Clinic Memphis Tennessee 38120 —
Texas Cancer Center Abilene Texas 79606 —
Texas Oncology Arlington Texas 76012 —
Southwest Regional Cancer Center Austin Texas 78705 —
Texas Oncology Cancer Center Austin Texas 78731 —
Mamie McFaddin Ward Cancer Center Beaumont Texas 77702 —
Texas Onoclogy PA - Bedford Bedford Texas 76022 —
Texas Cancer Center at Medical City Dallas Texas 75230 —
Texas Oncology, P.A. Dallas Texas 75231-1449 —
The Texas Cancer Center Dallas Texas 75237 —
TOPA Sammons Cancer Center Dallas Texas 75246 —
Texas Cancer Center Denton Texas 76210 —
El Paso Cancer Treatment Center El Paso Texas 79915 —
Texas Oncology, P.A. Fort Worth Texas 76104 —
San Antonio Tumor & Blood Clinic Fredericksburg Texas 78624 —
Texas Oncology, P.A. Garland Texas 75042 —
Texas Oncology, P.A. - Irving Irving Texas 75601 —
Lake Vista Cancer Center Lewisville Texas 75067 —
Longview Cancer Center Longview Texas 75601 —
S. Texas Cancer Center McAllen Texas 78503 —
Texas Cancer Center of Mesquite Mesquite Texas 75150 —
Allison Cancer Center Midland Texas 79701 —
West Texas Cancer Center Odessa Texas 79761 —
Hematology Oncology Associates of South Texas San Antonio Texas 78229 —
Tyler Cancer Center Tyler Texas 75702 —
Waco Cancer Care Research Center Waco Texas 76712 —
Texas Oncology, P.A. - Deke Slayton Cancer Center Webster Texas 77598 —
Virginia Oncology Associates Norfolk Virginia 23501 —
Onc and Hem Associates of SW VA, Inc. Salem Virginia 24153 —
Puget Sound Cancer Center - Edmonds Edmonds Washington 98026 —
Cancer Care Northwest-North Spokane Washington 99218 —
Northwest Cancer Specialists Vancouver Washington 98684 —
Froedtert Memorial Lutheran Hospital Milwaukee Wisconsin 53226 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 106 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00069745, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Aug 7, 2012 · Synced Oct 19, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT00069745 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →